Labile Anger During Interferon Alfa Treatment is Associated With a Polymorphism in Tumor Necrosis Factor α
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Inflammatory cytokines may influence both labile anger and depression. Both psychiatric conditions can occur during interferon alfa-based treatments. Evidence also indicates a central nervous system role for tumor necrosis factor alpha (TNF-alpha), whose expression may be increased by interferon alfa. A polymorphism in the promoter region of TNF-alpha has been associated with various inflammatory illnesses. We therefore hypothesized that this TNF-alpha polymorphism would influence susceptibility to psychiatric symptoms during interferon alfa therapy. METHODS: One hundred five patients with hepatitis C, initially without active major depression (major depressive disorder), were treated with interferon alfa and then prospectively monitored using the Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, the Beck Depression Inventory II, the Anger Irritability and Assault Questionnaire, and circulating TNF-alpha levels. The A-308G polymorphism (rs1800629) was determined using the 5'-nuclease assay. Repeated-measure mixed-effect analyses compared changes in symptoms over time. RESULT: Beck Depression Inventory II score increased during interferon alfa therapy (F = 6.2; P < 0.001), with 27% developing MDD. The TNF-alpha A allele was associated with worsened labile anger (F = 2.5; P < 0.05) and fatigue (F = 2.9; P < 0.05) during treatment but not with major depression incidence (chi = 0.0; P = 0.99) or increased Beck Depression Inventory II (F = 1.2; P = 0.31). Labile anger was not predicted by the serotonin transporter polymorphism (F = 0.8; P = 0.59). DISCUSSION: During treatment with an exogenous cytokine, vulnerability to worsening labile anger-distinct from major depression-is associated with genetic variability in TNF-alpha. This has implications both for patients being treated with interferon alfa and our understanding of genetic vulnerability for different subtypes of dysphoric and mood disorders.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dysfunction in the neural circuitry of emotion regulation–a possible prelude to violence
Davidson, R. J., Putnam, K. M., & Larson, C. L. (2000) · Science · doi:10.1126/science.289.5479.591 · Cited by 1,894
Synaptic scaling mediated by glial TNF-α
Stellwagen, D., & Malenka, R. C. (2006) · Nature · doi:10.1038/nature04671 · Cited by 1,715
Control of Synaptic Strength by Glial TNFα
Beattie, E. C., Stellwagen, D., Morishita, W., Bresnahan, J. C., Ha, B. K., Von Zastrow, M., Beattie, M. S., & Malenka, R. C. (2002) · Science · doi:10.1126/science.1067859 · Cited by 1,344
Capuron, L. (2002) · Neuropsychopharmacology · doi:10.1016/s0893-133x(01)00407-9 · Cited by 797
Hostile Marital Interactions, Proinflammatory Cytokine Production, and Wound Healing
Kiecolt-Glaser, J. K., Loving, T. J., Stowell, J. R., Malarkey, W. B., Lemeshow, S., Dickinson, S. L., & Glaser, R. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.12.1377 · Cited by 715
Depressive disorders and immunity: 20 years of progress and discovery
Irwin, M. R., & Miller, A. H. (2007) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2007.01.010 · Cited by 676
The immune-mediated alteration of serotonin and glutamate: towards an integrated view of depression
Müller, N., & Schwarz, M. J. (2007) · Molecular Psychiatry · doi:10.1038/sj.mp.4002006 · Cited by 670
Training and quality assurance with the structured clinical interview for DSM-iV (SCID-I/P)
Ventura, J., Liberman, R. P., Green, M. F., Shaner, A., & Mintz, J. (1998) · Psychiatry Research · doi:10.1016/s0165-1781(98)00038-9 · Cited by 591 · cited 1×
“Major depressive disorder during interferon alfa treatment was diagnosed using the Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition Axis I disorders.(75) The 21-item Beck Depression Inventory (BDI) II was used to assess depressive symptoms at week 2 and during mon…”
MethodO’Brien, S. M., Scully, P., Fitzgerald, P., Scott, L. V., & Dinan, T. G. (2007) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2006.05.013 · Cited by 355
Effects of Cytokines on Cerebral Neurotransmission: Comparison with the Effects of Stress
Dunn, A. J., Wang, J., & Ando, T. (1999) · Advances in Experimental Medicine and Biology · doi:10.1007/978-0-585-37970-8_8 · Cited by 316 · cited 1×
“Peripherally administered TNF-> can affect both neurotransmitter and endocrine release.(41,42) In humans, anti-TNF-> therapy may alleviate some mood-related symptoms.”
Wong, M.-L., Dong, C., Maestre-Mesa, J., & Licinio, J. (2008) · Molecular Psychiatry · doi:10.1038/mp.2008.59 · Cited by 295
Pro-inflammatory cytokines and treatment response to escitaloprsam in major depressive disorder
Eller, T., Vasar, V., Shlik, J., & Maron, E. (2008) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2007.09.015 · Cited by 290
Bull, S. J., Huezo-Diaz, P., Binder, E. B., Cubells, J. F., Ranjith, G., Maddock, C., Miyazaki, C., Alexander, N., Hotopf, M., Cleare, A. J., et al. (2009) · Molecular Psychiatry · doi:10.1038/mp.2008.48 · Cited by 228
Stress increases vulnerability to inflammation in the rat prefrontal cortex
de Pablos, R. M., Villarán, R. F., Argüelles, S., Herrera, A. J., Venero, J. L., Ayala, A., Cano, J., & Machado, A. (2006) · The Journal of Neuroscience · doi:10.1523/jneurosci.0802-06.2006 · Cited by 215
A different depression: clinical distinctions between bipolar and unipolar depression
Bowden, C. L. (2005) · Journal of Affective Disorders · doi:10.1016/s0165-0327(03)00194-0 · Cited by 207
The distinct temperament profiles of bipolar I, bipolar II and unipolar patients
Akiskal, H. S., Kilzieh, N., Maser, J. D., Clayton, P. J., Schettler, P. J., Traci Shea, M., Endicott, J., Scheftner, W., Hirschfeld, R. M. A., & Keller, M. B. (2006) · Journal of Affective Disorders · doi:10.1016/j.jad.2005.12.033 · Cited by 164
Kaneko, N., Kudo, K., Mabuchi, T., Takemoto, K., Fujimaki, K., Wati, H., Iguchi, H., Tezuka, H., & Kanba, S. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301137 · Cited by 152 · cited 1×
“Similarly, interferon alfa decreases cell proliferation in the hippocampus by induction of local cytokines.(100) Therefore, it is plausible that the A-308G polymorphism could particularly influence localized central nervous system expression of TNF-> during interferon alfa treatment.”
Cytokine-induced depression during IFN-α treatment: The role of IL-6 and sleep quality
Prather, A. A., Rabinovitz, M., Pollock, B. G., & Lotrich, F. E. (2009) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2009.07.001 · Cited by 139
Self-citationDepression following pegylated interferon-alpha: Characteristics and vulnerability
Lotrich, F. E., Rabinovitz, M., Gironda, P., & Pollock, B. G. (2007) · Journal of Psychosomatic Research · doi:10.1016/j.jpsychores.2007.05.013 · Cited by 100 · cited 6×
“However, worsened labile anger may be distinct from MDD.(22,23) Interferon alfaYbased therapies are the primary recommendation for chronic hepatitis C,(20,24) which affects more than 170 million people and results in approximately 10,000 deaths per year in the USA.”
InfluentialSelf-citationInhibition of peripheral TNF can block the malaise associated with CNS inflammatory diseases
Jiang, Y., Deacon, R., Anthony, D. C., & Campbell, S. J. (2008) · Neurobiology of Disease · doi:10.1016/j.nbd.2008.06.017 · Cited by 64 · cited 1×
“Fatigue and malaise are well-known symptoms of interferon alfa treatment,(23,97) and TNF-> has been associated with malaise in animal models.(98) Although TNF-> genotype was associated with increased fatigue, no mediation was found.”
Franzen, P. L., Buysse, D. J., Rabinovitz, M., Pollock, B. G., & Lotrich, F. E. (2010) · Psychiatry Research · doi:10.1016/j.psychres.2009.02.011 · Cited by 62 · cited 5×
“However, worsened labile anger may be distinct from MDD.(22,23) Interferon alfaYbased therapies are the primary recommendation for chronic hepatitis C,(20,24) which affects more than 170 million people and results in approximately 10,000 deaths per year in the USA.”
InfluentialSelf-citation
Cited by
Inflammatory cytokines in depression: neurobiological mechanisms and therapeutic implications
Felger, J. C., & Lotrich, F. E. (2013) · Neuroscience · doi:10.1016/j.neuroscience.2013.04.060 · Cited by 1,180
Self-citationInterferon-Induced Depression in Chronic Hepatitis C: A Systematic Review and Meta-Analysis
Udina, M., Castellví, P., Moreno-España, J., Navinés, R., Valdés, M., Forns, X., Langohr, K., Solà, R., Vieta, E., & Martín-Santos, R. (2012) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.12r07694 · Cited by 297
The evolutionary significance of depression in Pathogen Host Defense (PATHOS-D)
Raison, C. L., & Miller, A. H. (2013) · Molecular Psychiatry · doi:10.1038/mp.2012.2 · Cited by 253
Genetic Contributions of Inflammation to Depression
Barnes, J., Mondelli, V., & Pariante, C. M. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2016.169 · Cited by 237
Bufalino, C., Hepgul, N., Aguglia, E., & Pariante, C. M. (2013) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2012.04.009 · Cited by 228
“The authors found a significant association with labile anger and fatigue but not with depression (Lotrich et al., 2010).”
Metadata
- Authors
- Lotrich, F. E., Ferrell, R. E., Rabinovitz, M., & Pollock, B. G.
- Venue
- Clinical Neuropharmacology
- Published
- 2010-07
- Volume
- 33
- Issue
- 4
- Pages
- 191-197
- ISSN
- 0362-5664 (ISSN-L)
- OpenAlex
- W2089260826
- Cited by
- 41
- References
- 21
- FWCI
- 2.29
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.